| 產(chǎn)品編號(hào) | bs-13033R-Gold |
| 英文名稱 | Rabbit Anti-Drosha/Gold Conjugated antibody |
| 中文名稱 | 膠體金標(biāo)記的核糖核酸酶3/Drosha抗體 |
| 別 名 | DROSHA; Drosha double stranded RNA specific endoribonuclease; Drosha ribonuclease type III; Etohi2; HSA242976; Nuclear RNase III Drosha; p241; Protein Drosha; Putative protein p241 which interacts with transcription factor Sp1; Putative ribonuclease III; RANSE3L; Ribonuclease 3; Ribonuclease III; Ribonuclease III nuclear; Ribonuclease type III nuclear; RibonucleaseIII; RN 3; RN3; RNase 3; RNase III; RNase3; RNASE3L; RNaseIII; RNASEN; RNC_HUMAN; RNase III Drosha. |
| 規(guī)格價(jià)格 | 100ul/2980元 購(gòu)買 大包裝/詢價(jià) |
| 說(shuō) 明 書 | 100ul（10nm 15nm 35nm） |
| 研究領(lǐng)域 | 腫瘤 細(xì)胞生物 染色質(zhì)和核信號(hào) 表觀遺傳學(xué) |
| 抗體來(lái)源 | Rabbit |
| 克隆類型 | Polyclonal |
| 交叉反應(yīng) | Mouse, (predicted: Human, Rat, Dog, Cow, Horse, Sheep, ) |
| 產(chǎn)品應(yīng)用 | IEM=1:20-200 ICA=1:20-200 ChIP=1:20-200
not yet tested in other applications. optimal dilutions/concentrations should be determined by the end user. |
| 分 子 量 | 160kDa |
| 性 狀 | Lyophilized or Liquid |
| 濃 度 | 0.4mg/ml |
| 免 疫 原 | KLH conjugated synthetic peptide derived from human Drosha/RNase III Drosha |
| 亞 型 | IgG |
| 純化方法 | affinity purified by Protein A |
| 儲(chǔ) 存 液 | 0.02M TBS(pH8.2) with 1% BSA, 0.03% Proclin300. |
| 保存條件 | Store at 2-8 oC for 3-6 months. Avoid repeated freeze/thaw cycles. |
| 產(chǎn)品介紹 |
background: The ribonuclease III superfamily represents a structurally distinct group of double-strand-specific endonucleases with essential roles in RNA maturation, RNA decay, and gene silencing. Initial cleavage of microRNAs is catalysed by Drosha, a nuclease of the RNase III family, which acts on primary miRNA transcripts (pri-miRNAs) in the nucleus. Human Drosha is a component of two multi-protein complexes. The larger complex contains multiple classes of RNA-associated proteins including RNA helicases, proteins that bind double-stranded RNA, novel heterogeneous nuclear ribonucleoproteins and the Ewing's sarcoma family of proteins. The smaller complex is composed of Drosha and the double-stranded-RNA-binding protein, DGCR8. Function: Ribonuclease III double-stranded (ds) RNA-specific endoribonuclease that is involved in the initial step of microRNA (miRNA) biogenesis. Component of the microprocessor complex that is required to process primary miRNA transcripts (pri-miRNAs) to release precursor miRNA (pre-miRNA) in the nucleus. Within the microprocessor complex, DROSHA cleaves the 3' and 5' strands of a stem-loop in pri-miRNAs (processing center 11 bp from the dsRNA-ssRNA junction) to release hairpin-shaped pre-miRNAs that are subsequently cut by the cytoplasmic DICER to generate mature miRNAs. Involved also in pre-rRNA processing. Cleaves double-strand RNA and does not cleave single-strand RNA. Involved in the formation of GW bodies. Subunit: Component of the microprocessor complex, or pri-miRNA processing protein complex, which is composed of DROSHA and DGCR8. The microprocessor complex may contain multiple subunit of DGCR8 and DROSHA. Interacts with DGCR8, SP1 and SNIP1. Interacts with SRRT/ARS2. Subcellular Location: Nucleus. Nucleus; nucleolus. A fraction is translocated to the nucleolus during the S phase of the cell cycle. Localized in GW bodies (GWBs), also known as P-bodies. Tissue Specificity: Ubiquitous. Similarity: Contains 1 DRBM (double-stranded RNA-binding) domain. Contains 2 RNase III domains. Database links: Entrez Gene: 29102 Human Entrez Gene: 14000 Mouse Omim: 608828 Human SwissProt: Q9NRR4 Human SwissProt: Q5HZJ0 Mouse Unigene: 97997 Human Unigene: 293142 Mouse Important Note: This product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications. Dircer和Drosha是兩種核糖核酸酶是卵巢癌細(xì)胞中RNA干擾機(jī)制中的關(guān)鍵酶，Dircer和Drosha兩種酶的表達(dá)（數(shù)量）越高，存活時(shí)間越長(zhǎng)。美國(guó)科學(xué)家研究發(fā)現(xiàn)，卵巢癌患者存活率與兩種酶有關(guān)。美國(guó)MD安德森癌癥治療中心先后對(duì)111個(gè)和132個(gè)卵巢癌樣本進(jìn)行了分析。結(jié)果發(fā)現(xiàn)，人體內(nèi)兩種核糖核酸酶Dicer和Drosha含量高的患者平均存活11年，而含量低的患者平均只能活2.86年。Dicer的水平高低對(duì)卵巢癌患者尤其重要。這一發(fā)現(xiàn)有助于卵巢癌的診斷和治療。卵巢惡性腫瘤的發(fā)病率在女性常見惡性腫瘤中占2.4%～5.6%，在女性生殖道惡性腫瘤中占第三位。在婦女生殖道癌瘤中，卵巢癌造成的死亡人數(shù)高居首位。 |
